How much does Wellbutrin (bupropion) lower the seizure threshold?

Bupropion and Seizure Risk

Bupropion lowers the seizure threshold in a dose-dependent manner, with seizure incidence of approximately 0.1% at doses ≤300 mg/day, 0.4% at 300-450 mg/day, and increasing nearly tenfold at doses between 450-600 mg/day. 1

Quantified Seizure Risk by Dose

The FDA label provides the most authoritative data on seizure incidence:

• At ≤300 mg/day (sustained-release): ~0.1% (1 in 1,000 patients) 1
• At 300-450 mg/day (immediate-release): ~0.4% (4 in 1,000 patients) 1
• At 450-600 mg/day: Nearly 10-fold increase from the 450 mg/day rate 1
• Cumulative 2-year risk at ≤450 mg/day: 0.48% 2, 3

A large prospective study of 3,341 patients confirmed an observed seizure rate of 0.24% during the 8-week treatment phase and 0.40% for the entire study duration, with survival analysis yielding a cumulative rate of 0.36% at 300-450 mg/day 4.

Clinical Context and Risk Factors

The seizure risk is not uniform across all patients. Over half of reported seizure cases had identifiable predisposing factors 3. The FDA label explicitly identifies conditions that amplify seizure risk beyond the baseline dose-dependent effect 1:

Absolute contraindications (bupropion should not be used):

• Pre-existing seizure disorder
• Current or prior diagnosis of bulimia or anorexia nervosa
• Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs
• Severe head injury, arteriovenous malformation, CNS tumor or infection, severe stroke

Relative risk factors (use with extreme caution):

• Concomitant medications that lower seizure threshold (other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, systemic corticosteroids)
• Metabolic disorders (hypoglycemia, hyponatremia, severe hepatic impairment, hypoxia)
• Diabetes mellitus treated with oral hypoglycemics or insulin
• Excessive alcohol use
• Use of CNS stimulants, cocaine, or other illicit drugs

Formulation-Specific Considerations

Extended-release formulations warrant special attention. Delayed seizures can occur up to 24 hours after overdose of bupropion XL, with 32% of seizures occurring >8 hours post-ingestion 5. This delayed onset necessitates a minimum 24-hour observation period following overdose.

Notably, seizures can occur without preceding CNS toxicity (agitation, tremors, hallucinations), though these symptoms are more common in patients who subsequently seize 5.

Practical Risk Mitigation

The seizure risk can be substantially reduced through proper dosing strategy 1:

1. Never exceed 450 mg/day total dose (300 mg/day for XL formulation)
2. Use gradual titration: Start at 150 mg/day, increase no faster than weekly
3. Divide doses appropriately: For sustained-release, use twice-daily dosing; for XL, once-daily
4. Screen for risk factors before initiating treatment
5. Discontinue immediately and permanently if seizure occurs

Special Populations

In patients with brain metastases or elevated seizure risk (common in oncology settings), bupropion is explicitly contraindicated 6. Guidelines for obesity management similarly emphasize that bupropion-containing medications should be avoided in patients with epilepsy and used with extreme caution in those with seizure history 7.

For smoking cessation in cancer patients, the NCCN guidelines specifically note that bupropion is contraindicated in patients with seizure risks including stroke and brain metastases 6.

Comparative Context

The seizure incidence with bupropion at recommended doses (0.1-0.4%) falls within the range observed with other antidepressants 8, 3, 9. However, the dose-dependent escalation and specific contraindications make bupropion unique in requiring more stringent patient selection and monitoring.

Two case reports exist of seizures in breastfed infants whose mothers were taking bupropion, though this is exceedingly rare 10.